AstraZeneca PLC said Tuesday that a Phase 3 trial of Lynparza plus abiraterone showed that the drug combination reduced risk of disease progression in patients with prostate cancer.
The Anglo-Swedish pharma giant said Lynparza plus abiraterone reduced risk of disease progression by 34% compared with the standard of care.
Prostate cancer is the second most common cancer in male patients, causing around 375,000 deaths in 2020, AstraZeneca said.
Results also showed a favorable trend toward improved overall survival, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.